

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



10th July, 2020

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.

The Manager
Department of Corporate Relations,
BSE Limited
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

Dear Sir/ Madam,

Sub: Disclosure of Related Party Transaction under Regulation 23(9) of SEBI (LODR) Regulations, 2015, (Amendment) 2018.

We refer to the above captioned subject, we herewith submit to you the disclosure of related party transactions for the half year ended 31st March 2020 as required under Reg. 23(9) of SEBI (LODR) Regulations 2015, (Amendment) 2018.

Kindly take the same into your records.

Thanking You

Yours Faithfully

For **Krebs Biochemicals and Industries Limited**


Taruni Banda
Company Secretary

Disclosure of Related Party Transaction for the Half year ended 31st March 2020, pursuant to IND AS 24 (In pursuance with regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (Amendment), 2018)

Related Parties

Promoters/ Promoters Group:

Dr. R.T.Ravi- Chairman.
Mr. Avinash Ravi- Managing Director
Mrs. Hemalata Ravi w/o Dr. R.T.Ravi
Mr. Ajay Ravi S/o Dr. R.T.Ravi
Mr. Aditya Ravi S/o Dr. R.T.Ravi
M/s IPCA Laboratories Ltd

Associate Company

M/s IPCA Laboratories Ltd

Directors:

Dr. R.T. Ravi- Chairman.
Mr. Avinash Ravi- Managing Director
Mr. E. J. Babu- Director
Mr. Manish Jain- Director
Mr. Raj Kamal Prasad Verma- Independent Director
Mr. Satish Khivsara- Independent Director
Mr. G.V.L Prasad- Independent Director
Mrs. Malati Tangirala- Independent Director

Key Managerial Personnel

Ms. Taruni Banda- CS
Wef 09.08.2019

Companies in Which Directors Relatives are Directors

M/s Ravi Agrochemicals Pvt Ltd



Krebs Biochemicals & Industries Ltd

Related Parties Disclosure:

(Rs. In Lacs)		
S#	Particulars	For the Period from Oct 2019 to Mar 2020
I	Particulars of transactions during the period	
a	Remuneration paid/payable to Key Management Personnel	29.95
b	Sitting fees paid/payable to Directors	3.80
c	ICD Received from Associate Company	1,015.00
d	Interest paid/payable to Associate company	240.91
e	Purchases from Associate (Including Taxes)	539.47
f	Sales and Services made to Associate (Including Taxes, Excluding Cash discount)	2,675.49
g	Advance received from Associate company	964.20
h	Amount received against Shares Issued to Ipca Laboratories Ltd	1,178.20
i	Amount received against Non convertible, Redeemable, Non-cumulative preference Shares issued to Ipca Laboratories Ltd	3,000.00
j	Amount received against Share Warrants issued to Ipca Laboratories Ltd	765.40
k	Amount paid/payable to Director	10.83
l	Amount paid/payable to Directors & Key Management Personnel & Relatives of Key Management personnel & Companies in which Directors Relatives are Directors	1.35

II Balances Payable/Receivable to Associates/Key Management personnel etc.		(Rs. In Lacs)
S#	Particulars	As at 31st March 2020
a	Deposit Payable to Associate Company	4,500.00
b	ICD Payable to Associate Company	3,247.50
c	Balance Payable to Associate Company	1,221.38
d	Ipca Laboratories Ltd - Non convertible, Redeemable, Non-cumulative preference shares	3,000.00
e	Amount Payable to Director	402.10
f	Amount payable to Directors & Key Management Personnel & Relatives of Key Management personnel & Companies in which Directors Relatives are Directors	140.32

For Krebs Biochemicals and Industries Limited


Ravi Babu
Head- Accounts